Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 7/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935059 | 0.80 | HPGD (0.54) | KDM4CP2RX7PSMB1PSMB5PSMB2 | |
| SCHEMBL5444425 | 0.79 | SMN1; SMN2 (0.51) | DNM1BCHEP2RX7PDCD1LG2CD274 | |
| SCHEMBL4294535 | 0.75 | KDM4C (0.48) | KDM4CP2RX7CD274ALDH1A1HPGD | |
| SCHEMBL18076397 | 0.74 | DNM1 (0.56) | DNM1BCHEALDH1A1HPGD | |
| SCHEMBL7617265 | 0.73 | BCHE (0.55) | BCHEPSMB1PSMB5PSMB2 | |
| SCHEMBL7617259 | 0.73 | BCHE (0.55) | BCHEPSMB1PSMB5PSMB2 | |
| SCHEMBL5437755 | 0.72 | BCHE (0.48) | BCHE | |
| SCHEMBL5670334 | 0.72 | P2RX7 (0.52) | KDM4CP2RX7ALDH1A1HPGD | |
| SCHEMBL5433210 | 0.70 | OPRK1 (0.51) | ALDH1A1 | |
| SCHEMBL3351750 | 0.70 | F2 (0.46) | DNM1BCHEPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | KDM4C 2130/4885DNM1 1107/4885BCHE 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.